TNFSF13B and myasthenia gravis: We have also found such differences within AChRAb(–)MuSK(–) MG patients: those treated with CS within last three months as well as patients treated with CS whenever in the past showed significantly lower BAFF levels in comparison with untreated (613.97 ± 127.7 pg/ml vs. 855.4 ± 258.6 pg/ml, respectively; p = 0.009; 626.6 ± 147.9 vs. 873.9 ± 257.2 pg/ml, respectively; p = 0.006).